Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy

International Journal of Oncology

Volumn 47, Issue 5, 2015, Pages 1735-1748

  Vega, Gabriel G ^a   Franco Cea, Luz Areli ^a   Huerta Yepez, Sara ^b   Mayani, Héctor ^a   Morison, Sherie L ^c   Bonavida, Benjamin ^c   Vega, Mario I ^a,b,c  

^a HOSPITAL DE ONCOLOGÍA   (Mexico)

^b HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti.CD20.hIFN ; Chemosensitivity; Cytotoxicity; IFN ; Lymphoma; Rituximab resistance

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTINEOPLASTIC AGENT; BENDAMUSTINE; CD20 HIFN ALPHA FUSION PROTEIN ANTIBODY; CISPLATIN; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY; PROTEIN KINASE C DELTA; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ANTIBODY; RITUXIMAB; ROTTLERIN; STAT1 PROTEIN; UNCLASSIFIED DRUG; ALPHA INTERFERON; CD20 ANTIGEN; IMIDAZOLE DERIVATIVE; ONCOPROTEIN; PYRIDINE DERIVATIVE;

2F7 CELL LINE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MOLECULAR CLONING; MONOTHERAPY; NON-HODGKIN LYMPHOMA CELL LINE; PRIORITY JOURNAL; RAMOS CELL LINE; SIGNAL TRANSDUCTION; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LYMPHOMA, B-CELL; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD20; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; IMIDAZOLES; INTERFERON-ALPHA; LYMPHOMA, B-CELL; MICE; ONCOGENE PROTEINS, FUSION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; RITUXIMAB;

EID: 84942903515     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3170     Document Type: Article

References (50)

1. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236, 2011.
2. zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP, et al: NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw 8: 288-334, 2010.
3. Coiffer B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, et al: Long-term outcome of patients in the LNH-98.5 trial, the frst randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116: 2040-2045, 2010.
4. Glennie MJ, French RR, Cragg MS and Taylor RP: Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 44: 3823-3837, 2007.
5. Rezvani AR and Maloney DG: Rituximab resistance. Best Pract Res Clin Haematol 24: 203-216, 2011.
6. Vega MI, Martinez-Paniagua M, Jazirehi AR, Huerta-Yepez S, Umezawa K, Martinez-Maza O and Bonavida B: The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resis-tant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. Leuk Lymphoma 49: 1982-1994, 2008.
7. Shimizu R, Kikuchi J, Wada T, Ozawa K, Kano Y and Furukawa Y: HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia 24: 1760-1768, 2010.
8. Kimby E: Biological therapy doublets: Pairing rituximab with interferon, lenalidomide, and other biological agents in patients with follicular lymphoma. Curr Hematol Malig Rep 7: 221-227, 2012.
9. Wahlin BE, Sundström C, Holte H, Hagberg H, Erlanson M, Nilsson-Ehle H, Lindén O, Nordström M, Ostenstad B, Geisler CH, et al: T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab. Clin Cancer Res 17: 4136-4144, 2011.
10. Davis TA, Maloney DG, Grillo-López AJ, White CA, Williams ME, Weiner GJ, Dowden S and Levy R: Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and inter-feron-alpha-2a. Clin Cancer Res 6: 2644-2652, 2000.
11. Sacchi S, Federico M, Vitolo U, Boccomini C, Vallisa D, Baldini L, Petrini M, Rupoli S, Di Raimondo F, Merli F, et al; GISL: Clinical activity and safety of combination immuno-therapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica 86: 951-958, 2001.
12. Kimby E, Jurlander J, Geisler C, Hagberg H, Holte H, Lehtinen T, Ostenstad B, Hansen M, Osterborg A, Lindén O, et al; Nordic Lymphoma Group: Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma 49: 102-112, 2008.
13. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH and Borden EC: Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8: 237-249, 2003.
14. Hayashida M, Hoshika A, Kanetaka Y, Yanase N and Mizuguchi J: IFN-alpha sensitizes daudi B lymphoma cells to anti-IgM induced loss of mitochondrial membrane potential through activation of c-Jun NH(2)-terminal kinase. J Interferon Cytokine Res 26: 421-429, 2006.
15. Gutterman JU: Cytokine therapeutics: Lessons from interferon alpha. Proc Natl Acad Sci USA 91: 1198-1205, 1994.
16. Spielberger RT, Mick R, Ratain MJ and Golomb HM: Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986. Leuk Lymphoma 14 (Suppl 1): 89-93, 1994.
17. Yanase N, Hayashida M, Kanetaka-Naka Y, Hoshika A and Mizuguchi J: PKC-δ mediates interferon-α-induced apoptosis through c-Jun NH(2)-terminal kinase activation. BMC Cell Biol 13: 7-15, 2012.
18. Schrama D, Reisfeld RA and Becker JC: Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5: 147-159, 2006.
19. Xuan C, Steward KK, Timmerman JM and Morrison SL: Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood 115: 2864-2871, 2010.
20. Jazirehi AR, Vega MI and Bonavida B: Development of ritux-imab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 67: 1270-1281, 2007.
21. Vega MI, Huerta-Yepez S, Martinez-Paniagua M, Martinez-Miguel B, Hernandez-Pando R, González-Bonilla CR, Chinn P, Hanna N, Hariharan K, Jazirehi AR, et al: Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. Clin Cancer Res 15: 6582-6594, 2009.
22. Alas S, Emmanouilides C and Bonavida B: Inhibition of inter-leukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7: 709-723, 2001.
23. Bonavida B: Rituximab-induced inhibition of antiapoptotic cell survival pathways: Implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 26: 3629-3636, 2007.
24. Vega MI, Huerta-Yepaz S, Garban H, Jazirehi A, Emmanouilides C and Bonavida B: Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistance. Oncogene 23: 3530-3540, 2004.
25. Czuczman MS and Gregory SA: The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk Lymphoma 51: 983-994, 2010.
26. Kotenko SV and Pestka S: Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene 19: 2557-2565, 2000.
27. Stark GR, Kerr IM, Williams BR, Silverman RH and Schreiber RD: How cells respond to interferons. Annu Rev Biochem 67: 227-264, 1998.
28. Salamon D, Adori M, He M, Bönelt P, Severinson E, Kis LL, Wu L, Ujvari D, Leveau B, Nagy N, et al: Type I interferons directly down-regulate BCL-6 in primary and transformed germinal center B cells: Differential regulation in B cell lines derived from endemic or sporadic Burkitt's lymphoma. Cytokine 57: 360-371, 2012.
29. Basso K, Saito M, Sumazin P, Margolin AA, Wang K, Lim WK, Kitagawa Y, Schneider C, Alvarez MJ, Califano A, et al: Integrated biochemical and computational approach identi-fes BCL6 direct target genes controlling multiple pathways in normal germinal center B cells. Blood 115: 975-984, 2010.
30. Niu H, Ye BH and Dalla-Favera R: Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor. Genes Dev 12: 1953-1961, 1998.
31. Phan RT, Saito M, Kitagawa Y, Means AR and Dalla-Favera R: Genotoxic stress regulates expression of the proto-oncogene Bcl6 in germinal center B cells. Nat Immunol 8: 1132-1139, 2007.
32. Basso K and Dalla-Favera R: Roles of BCL6 in normal and transformed germinal center B cells. Immunol Rev 247: 172-183, 2012.
33. Cragg MS, Walshe CA, Ivanov AO and Glennie MJ: The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 8: 140-174, 2005.
34. Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, Beaumont T, Tedder TF, van Noesel CJ, Eldering E, et al: CD20 defciency in humans results in impaired T cell-independent antibody responses. J Clin Invest 120: 214-222, 2010.
35. Xu D, Staedman A and zhang L: CD20 antibody primes B lymphocytes for type I interferon production. PLoS One 8: e67900, 2013.
36. Polyak MJ, Tailor SH and Deans JP: Identifcation of a cyto-plasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J Immunol 161: 3242-3248, 1998.
37. Jarvis RM, Chamba A, Holder MJ, Challa A, Smith DC, Hodgkin MN, Lord JM and Gordon J: Dynamic interplay between the neutral glycosphingolipid CD77/Gb3 and the therapeutic antibody target CD20 within the lipid bilayer of model B lymphoma cells. Biochem Biophys Res Commun 355: 944-949, 2007.
38. Holder MJ, Chamba A, Hardie DL, Deans JP and Gordon J: Improved access to CD20 following B cell receptor cross-linking at Burkitt's lymphoma cell surfaces. Leuk Res 28: 1197-1202, 2004.
39. Khine AA and Lingwood CA: Functional significance of globotriaosyl ceramide in interferon-alpha(2)/type 1 interferon receptor-mediated antiviral activity. J Cell Physiol 182: 97-108, 2000.
40. Maloney MD, Binnington-Boyd B and Lingwood CA: Globotriaosyl ceramide modulates interferon-alpha-induced growth inhibition and CD19 expression in Burkitt's lymphoma cells. Glycoconj J 16: 821-828, 1999.
41. Rossi EA, Goldenberg DM, Cardillo TM, Stein R and Chang CH: CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood 114: 3864-3871, 2009.
42. Rossi EA, Rossi DL, Stein R, Goldenberg DM and Chang CH: A bispecifc antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells. Cancer Res 70: 7600-7609, 2010.
43. Brodie C and Blumberg PM: Regulation of cell apoptosis by protein kinase c delta. Apoptosis 8: 19-27, 2003.
44. Jackson DN and Foster DA: The enigmatic protein kinase Cdelta: Complex roles in cell proliferation and survival. FASEB J 18: 627-636, 2004.
45. Reyland ME: Protein kinase Cdelta and apoptosis. Biochem Soc Trans 35: 1001-1004, 2007.
46. Saijo K, Mecklenbräuker I, Schmedt C and Tarakhovsky A: B cell immunity regulated by the protein kinase C family. Ann NY Acad Sci 987: 125-134, 2003.
47. Yanase N, Ohshima K, Ikegami H and Mizuguchi J: Cytochrome c release, mitochondrial membrane depolarization, caspase-3 activation, and Bax-alpha cleavage during IFN-alpha-induced apoptosis in Daudi B lymphoma cells. J Interferon Cytokine Res 20: 1121-1129, 2000.
48. Yanase N, Hata K, Shimo K, Hayashida M, Evers BM and Mizuguchi J: Requirement of c-Jun NH2-terminal kinase activation in interferon-alpha-induced apoptosis through upregu-lation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in Daudi B lymphoma cells. Exp Cell Res 310: 10-21, 2005.
49. Kaur S, Parmar S, Smith J, Katsoulidis E, Li Y, Sassano A, Majchrzak B, Uddin S, Tallman MS and Fish EN: Role of protein kinase C-delta (PKC-delta) in the generation of the effects of IFN-alpha in chronic myelogenous leukemia cells. Exp Hematol 33: 550-557, 2005.
50. Kumar A, Commane M, Flickinger TW, Horvath CM and Stark GR: Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 278: 1630-1632, 1997.